

S/N 09/589,476

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Dennis A. Carson <i>et al.</i>	Examiner:	Frederick F. Krass
Serial No.:	09/589,476	Group Art Unit:	1614
Filed:	June 07, 2000	Docket:	103.021US1
Title:	USE OF ETODOLAC IN THE TREATMENT OF CANCER		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicants' Representatives with the next official communication.

Pursuant to 37 C.F.R. § 1.98(a)(2), copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicants have not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicants respectfully request that notice of such requirement be directed to Applicants' below-signed Representative. Applicants acknowledge the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. § 1.98(a)(2).

Pursuant to 37 C.F.R. § 1.97(c)(2), please charge Deposit Account 19-0743 in the amount of \$180.00 as set forth in 37 C.F.R. § 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Serial No :09/589,476

Filing Date: June 07, 2000

Title: USE OF ETODOLAC IN THE TREATMENT OF CANCER

Page 2

Dkt: 103.021US1

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,


DENNIS A. CARSON ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.  
P.O. Box 2938  
Minneapolis, MN 55402  
(612) 371-2106


Date 6 September 2005

By

  
Katharine A. Jackson Huebsch  
Reg. No. 47,670

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 6 day of September, 2005.


LISA ROSORSKE  
Name

  
Signature

Substitute for form 1449A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/589,476
Filing Date	June 7, 2000
First Named Inventor	Carson, Dennis
Group Art Unit	1614
Examiner Name	Krass, Frederick

Sheet 1 of 1

Attorney Docket No: 103.021US1

## **US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Filing Date If Appropriate
	US-4,041,169	08/09/1977	Demerson, Christopher A., et al.	10/28/1976
	US-4,179,503	12/18/1979	Asselin, Andre A., et al.	05/08/1978
	US-5,780,435	07/14/1998	Garnick, M. B., et al.	12/15/1995
	US-6,110,955	08/29/2000	Nudelman, A., et al.	03/11/1997
	US-6,300,313	10/09/2001	Engel, J., et al.	09/22/1999

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	CA-1299577	04/28/1992	Guindon, Yvan, et al.	
	GB-1436893	05/26/1976	Shering Aktiengesellschaft, et al.	
	WO-02/02125A1	01/10/2002	Tait, Russell, et al.	

## **OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		<u>Drug Facts and Comparisons, 1995 Edition, Wolters Kluwer Co.,(1995),2775-2789</u>	
		"International Search Report for PCT/US2004/032185", <u>April 10, 2005</u>	
		BRENNA, ELISABETTA, et al., "New Enzymatic and Chemical Approaches to Enantiopur Etodolac", <u>Tetrahedron, Vol. 53, No. 52, (1997),17769-17780</u>	
		KOLLURI, S. K., et al., "The R-Enantiomer of the Nonsteroidal Antiinflammatory Drug Etodolac Binds Retinoid X Receptor and Induces Tumor-Selective Apoptosis", <u>Proc. Natl. Acad. Sci. USA., 102(7), (2005),2525-2530</u>	
		MYCEK, M. J., et al., "Anticancer Drugs", <u>Lippincott's Illustrated Reviews: Pharmacology, Second Edition, (1997),373; 387-395</u>	

**EXAMINER**

**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached